NASDAQ · OTLK
Healthcare · Biotechnology
$0.47
Up+$0.00 (+0.23%)
Updated Nov 3, 2026, 12:24 AM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · OTLK
1M range · 0 trading sessions · Daily adjusted prices
OTLK does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning OTLK.
Company
Market Activity
Research & News
OTLK research
Company profile and research snapshot.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 11, 2026 | Ascendiant Capital | Buy | — |
| Aug 14, 2026 | BTIG | Buy | — |
| Jul 27, 2026 | BTIG | Buy | — |
| Jul 27, 2026 | HC Wainwright & Co. | Neutral | — |
| Jun 11, 2026 | Ascendiant Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 5, 2026
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today provided an update following its recent Type A
Benzinga · Feb 19, 2026
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases and Mediconsult AG, Switzerland's leading full-service
Benzinga · Feb 18, 2026
HC Wainwright & Co. analyst Douglas Tsao reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Neutral and maintains $0.5 price target.
Benzinga · Feb 17, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OTLK.
